Background
Gilead Sciences alleged that Rx Valet, Advanced Pharmacy, Affordable RX Meds, and executive Gregory Santulli arranged to import and distribute foreign-market versions of Gilead-branded prescription drugs in the United States. The arrangement came to light after a Maryland patient received Biktarvy packaged for Turkey, with Turkish-language labeling and without warnings and other information accompanying the U.S. version. Although the tablets were authentic and chemically identical to U.S.-market Biktarvy, Gilead had not authorized their domestic sale.
Gilead also sued third-party administrator Meritain Health and pharmacy benefit manager ProAct for contributory infringement. It alleged that their patient-data, claims-processing, and referral services facilitated the importation program despite their knowledge of the foreign sourcing and differences between imported and domestic drugs. The district court entered a preliminary injunction prohibiting the defendants from advertising, selling, importing, or facilitating the importation of Gilead-branded medications from abroad.
The Court’s Holding
The Fourth Circuit affirmed. It held that Gilead was likely to succeed on its direct-infringement claims because the imported medications were not genuine goods for Lanham Act purposes. The foreign products materially differed from their U.S. counterparts in labeling, warnings, prescribing information, regulatory disclosures, and identifying information. They also bypassed Gilead’s domestic quality controls for temperature monitoring, chain-of-custody tracing, recalls, and authorized distribution. Chemical identity did not eliminate those differences, and the first-sale doctrine therefore did not bar Gilead’s claims.
The court also held that Gilead was likely to establish contributory infringement by Meritain and ProAct. Under Fourth Circuit precedent, a service provider may be liable when it continues supplying services to identified direct infringers while knowing or having reason to know of the infringement; advance notice from the trademark owner and a separate showing of control over the means of infringement are not required. The FDCA did not preclude Gilead’s claims because liability turned on material differences under trademark law, not on judicial enforcement or interpretation of the FDCA.
The court upheld the remaining preliminary-injunction findings. Gilead’s investigation and referral of the matter to the FDA adequately explained its delay in suing and did not rebut the statutory presumption of irreparable harm. The balance of equities and public interest also favored relief. The court declined pendent appellate review of the denial of Santulli’s personal-jurisdiction motion and held that he had not preserved his distinct argument that the district court needed to find a reasonable probability of personal jurisdiction before enjoining him.
Key Takeaways
- Authentic gray-market goods may still infringe when they materially differ from authorized domestic products or bypass the trademark owner’s legitimate quality-control system.
- For prescription drugs, differences in language, safety warnings, regulatory information, traceability, shipping controls, and recall coverage can be material even when the drug formulations are identical.
- In the Fourth Circuit, contributory trademark liability for service providers follows Inwood’s inducement-or-knowledge test; prior notice from the trademark owner and a separate degree-of-control element are not required.
Why It Matters
The decision applies the material-differences doctrine to gray-market prescription drugs and confirms that a manufacturer’s trademark interests encompass the safety information and distribution safeguards associated with its domestic products. Businesses cannot treat foreign-market medication as genuine for Lanham Act purposes merely because the manufacturer made it and its chemical formulation matches the U.S. version.
The ruling also clarifies the exposure of benefit administrators, pharmacy benefit managers, and other intermediaries. A company that knowingly continues supplying operational services to identified participants in an infringing importation program may face contributory liability even without first receiving a cease-and-desist letter.